April 2013. The transmission system operator shall conduct capacity auctions on an auction internet platform. The registration on the auction platform and the execution of auctions shall be subject to the “General Terms and Conditions for the Use of the PRISMA Capacity Platform“ as amended. In order to participate in the auctions, the system user also has to register on the auction platform of the transmission system operator. After successful registration for TAG auctions on PRISMA, the system user will be electronically informed about the further steps for registration on the TSO`s auction platform.
April 2013. 62 It follows from my findings above that, after Azimut sold the Azimut 100G #12, Cip was entitled to recover the €1m Deposit, for the basis upon which he had paid the €1m Deposit, viz, that Azimut would hold the two Azimut 100 yachts off the market for him until 15 May 2013 for him to choose between them, whereupon the €1m Deposit would become the initial down payment for the chosen yacht, had totally failed. Both Xxxxx and Xxxxxx admitted this (see [56] above) in cross-examination, and I so find. The 8 May 2013 Meeting 63 The defendant’s case is that, during the 8 May 2013 Meeting, Cip agreed with Grange and/or represented that the €1m Deposit should be paid to Azimut as a non-refundable deposit to reserve the Azimut 100L #15 and the Azimut 100G #15 (see [25(b)] above). The defendant relies on Xxxxxx’s evidence that he told Cip that the €1m Deposit would be non-refundable if Cip did not purchase either yacht, and that Cip acknowledged this position.77 76 Transcript, 13 April 2017, p 23. 77 Xxxxxx’s AEIC at paras 14 and 16. 64 I find that there was no such agreement or representation. 65 First, as the plaintiff emphasises,78 the defendant has not produced any documentary evidence of the alleged agreement or representation. In particular:
April 2013. 6. Roles and responsibilities The EMCDDA is responsible for allocating sufficient human or financial resources in line with EU rules and regulations, to fulfil the following r xxxx and responsibilities:
April 2013. Employees in an active pay status and who are below the maximum step shall be eligible to move to the next step effective the beginning of the first full pay period in April 2013, provided they have been employed continuously by the Commonwealth since April 30, 2012. Full-time employees who are at Step I and who have been employed continuously by the Commonwealth since April 30, 2012 shall receive the annual amount of a 2.25% increase in the form of a one-time cash payment rounded to the nearest dollar. Intermittent Liquor Store Clerks who are at Step I and have been employed continuously by the Commonwealth since April 30, 2012 shall receive a pro rata share of the one-time cash payment of 2.25% based on the number of hours worked in the prior fiscal year.
April 2013. Parties: The Company; and Schlumberger Schlumberger’s principal business is investment holding. Schlumberger is a subsidiary of Schlumberger Limited, which is a global oilfield services company. Schlumberger is a substantial shareholder of the Company interested in approximately 19.68% of the issued share capital of the Company as at the date of this announcement. Accordingly, Schlumberger is a connected person of the Company for the purpose of the Listing Rules and the entering into of the Master Agreement between the Company and Schlumberger constitutes continuing connected transactions for the Company under Chapter 14A of the Listing Rules. Subject: Pursuant to the Master Agreement, the Group will supply the Products and Services to the Schlumberger Group and Schlumberger will supply and will procure the Affiliates to supply to the Group the Products and Services for a period of three financial years until 31 December 2015. Price: The basis of determining the prices for the Products and Services to be supplied by the Company or Schlumberger or Affiliates under the Master Agreement will be in accordance with the prevailing market prices of similar products or services. Annual Caps: The parties have agreed that the annual transaction amount under the Master Agreement will not exceed the following annual caps: 31 December 31 December 31 December 2013 2014 2015 US$’000 US$’000 US$’000 80,000 100,000 120,000 80,000 100,000 120,000 For the financial year ending Supply of Products and Services by the Group to Schlumberger or Affiliates Supply of Products and Services by Schlumberger or Affiliates to the Group The cap amounts for the procurement from the Schlumberger Group by the Group are determined with reference to the historical transactional amount and the projected demand for Products and Services as the Group grows its business. The Company and the Schlumberger Group had business transactions in previous years. The historical transactional amounts between the Group and the Schlumberger Group are as follows: Year 2011 2012 US$’000 US$’000 Supply of Products and Services by Schlumberger to the Group 693 21,880 Note:
April 2013. Gateway Process: the process for securing Funder approval at the various stages of the Project as set out in Appendix 1. Gateway Stage: each stage of the Project as set out within the Gateway Process. Governing Body: the Executive Board of the Recipient. Grant: the total sum of Eight million eight hundred and sixty three thousand four hundred and ninety eight pounds and three xxxxx (£8,863,498.03) (together with any additional sums paid from the QRA) to be paid to the Recipient in accordance with this Agreement. Grant Period: the period for which the Grant is awarded starting on the Commencement Date and ending on 31 March 2018 or such later date as shall be agreed by the Funder. Intellectual Property Rights: all patents, copyrights and design rights (whether registered or not) and all applications for any of the foregoing and all rights of confidence and Know-How however arising for their full term and any renewals and extensions. Know-How: information, data, know-how or experience whether patentable or not and including but not limited to any technical and commercial information relating to research, design, development, manufacture, use or sale.
April 2013. Uganda and Kenya have agreed to coordinate efforts to improve animal health in their border areas. Representatives from both countries signed a Memorandum of Understanding (MoU) in the border town of Moroto, Uganda, today. The agreement is a unique step towards building the resilience of communities in the region. The MoU will synchronize the cross-border animal health programs of both countries. Kenya and Uganda are committed to coordinating investments in the districts and creating better access to services for pastoralists. Disease control activities will be harmonized while information will be shared. The communities living along the Kenya-Uganda border in the Pokot and Turkana Counties of Kenya and the Karamoja Sub-region of Uganda are among the first to benefit from the agreement. Thousands of families in these areas depend on livestock as the primary source of livelihood. In search of pastures and water sources and in pursuit of trading opportunities, pastoralists frequently cross the Uganda-Kenyan border with their livestock. “The new partnership will improve animal health service delivery as coordination and information sharing between both countries will be strengthened,” says IGAD’s Executive Secretary H.E Ambassador (Eng.) Xxxxxxx X. Xxxxxx. “As a result local trade will be stimulated while resilience of local communities is further strengthened.” Generally, there has been limited coordination in animal health across countries and other service providers in Eastern Africa. The agreement, which bridges this gap, was initiated by technical officers on the ground, led by the NGO ACTED with funding from ECHO. With help from RISPA, an IGAD-FAO partnership programme funded by the European Union, the cross-border animal health coordination was moved up the political agenda, resulting in today’s agreement. “Kenya and Uganda have committed themselves to harmonize their animal health initiatives, bringing the needs of the communities to the front,” adds RISPA’s Project Coordinator Emmanuella Olesambu. The collaboration is a consequence of measures taken by governments after the devastating drought that hit the Horn of Africa in 2011 and which affected over 10 million people in Somalia, Kenya and Ethiopia. After the drought governments spearheaded initiatives to increase resilience of vulnerable communities in arid and semi-arid areas. “This agreement will boost cross-border trade in livestock and livestock commodities between the two countries and harmon...
April 2013. Heptares Achieves All Research Milestones and Receives Milestone Payment From GPCR Drug Discovery Agreement With Takeda Pharmaceutical Co. Ltd. (TKPYY) 4/29/2013 8:28:30 AM WELWYN GARDEN CITY, England and BOSTON, April 29, 2013 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery and development company, announces it has achieved all milestones in its collaboration with Takeda Pharmaceutical Company. By achieving these milestones, Heptares will receive a significant payment from Takeda, under the terms of the agreement signed by the two companies in 2011. The agreement is focused on a single GPCR target nominated by Takeda that, until now, has proved intractable to rational drug discovery efforts due to its instability when removed from the cell membranes and the resulting lack of insight into its structure. Over the course of the collaboration Heptares has leveraged its structure-based drug design (SBDD) approach to GPCRs and proprietary technologies to generate the first-ever stabilised form of the target in a clinically relevant conformation enabling a series of novel lead candidates against the target to be designed. Xxxxxxxxx Xxxxxxxx, General Manager Pharmaceutical Research Division, Takeda said: "We are impressed with the efficiency and results from this partnership with Heptares. In achieving these milestones, the Heptares team has demonstrated its ability to design new, high-quality small molecules to a previously challenging GPCR target. We look forward to continuing our partnership and taking these leads forward into pre-clinical development." "Our partnership with Takeda provides an excellent validation of our GPCR-focused structure-based drug design approach and capabilities," said Xxxxxxx Xxxx, CEO of Heptares. "We see similar good progress in our other partnerships where to date we have hit every milestone. This success, in turn, provides us with an important source of capital, which has enabled us to build an impressive proprietary pipeline and provided funds to advance our first-ever selective M1 agonist into first clinical studies later this year." Under the terms of the agreement, Takeda receives worldwide commercial rights to new drugs emerging from the collaboration. Upon signing, Xxxxxxxx received an upfront payment of £1.7 million and an investment in an equity stake of approximately £2.8 million purchased by Takeda Ventures Inc., a wholly-owned subsidiary of Takeda. Heptares has also now received £1 million in rese...
April 2013. Other issues to be addressed within Phase 2, will include issues relating to:- • Accommodation • Marketing and Communication • Training • Information a& Clinical Governance/Risk Management • Performance Management • HR Implications Phase 1 of Implementation
